EDSS

Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab

Retrieved on: 
星期四, 四月 25, 2024
American Academy, Brain, White matter, Mass, Expanded access, Hospital, Encephalitis, PET, Research, EDSS, Patient, MFIS, Fatigue, DSM-IV codes, Harvard Medical School, Associate, Disability, PIRA, Medical imaging

White Matter Z-scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in structures of the brain.

Key Points: 
  • White Matter Z-scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in structures of the brain.
  • We calculated White Matter Z-scores to measure the effect of intranasal foralumab on microglial activation at baseline and then after foralumab treatment for three months.
  • I welcome the publication of Dr. Singhal’s [F18]PBR06-PET research paper, highlighting these combined findings in Clinical Nuclear Medicine,” commented Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences.
  • *EA5 showed a worsening in their White Matter Z-Score at three months during a pseudo-exacerbation of the patient’s trigeminal neuralgia.

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program

Retrieved on: 
星期一, 四月 22, 2024
EAP, Mass, Hospital, EDSS, Patient, MFIS, Fatigue, Neurology, Harvard Medical School, Multiple sclerosis, Central nervous system, Microsoft Access, Nursing

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced additional positive clinical results from its intermediate sized Expanded Access Program (EAP) for non-active secondary progressive multiple sclerosis (na-SPMS) patients.

Key Points: 
  • NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced additional positive clinical results from its intermediate sized Expanded Access Program (EAP) for non-active secondary progressive multiple sclerosis (na-SPMS) patients.
  • The data demonstrate multiple improvements in foralumab-treated patients, with 70% showing an improvement in fatigue after six months of follow-up.
  • Fatigue is a debilitating symptom for many MS patients and is measured by the Modified Fatigue Impact Scale (MFIS).
  • The findings, which are summarized in Table 1 below, show broad-based six-month improvements across various key measures for multiple sclerosis.

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Retrieved on: 
星期四, 四月 18, 2024
American Academy, Mass, Hospital, Stabilizer, White matter, PET, EDSS, Human, Patient, MFIS, Fatigue, DSM-IV codes, Harvard Medical School, Biomarker, Annual general meeting, Associate, Microsoft Access, Neuro, PIRA, Medical imaging

The presentation includes new, encouraging quantitative imaging data from foralumab’s intermediate- size patient population Expanded Access Program.

Key Points: 
  • The presentation includes new, encouraging quantitative imaging data from foralumab’s intermediate- size patient population Expanded Access Program.
  • Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences, commented, “Tiziana is taking a leadership role in focusing on this subset of progressive MS where there are no effective treatments.
  • The study is designed to be open-label and part of the Expanded-Access Program evaluating foralumab in na-SPMS patients that is currently underway.
  • This trial ( NCT06292923 ) is important because if the potential to slow disease progression is demonstrated this would align with early treatment intervention.

EMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefits

Retrieved on: 
星期四, 二月 29, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Senior, Merck, Quality of life, Merck Serono, Treatment, Disease, Multiple sclerosis, System, Safety, EDSS, Health care, Bawskee 3.5, SDMT, Patient, Employment, Cladribine, Sclerosis, RMS, Tablet, Merck Group, MRI, Pharmaceutical industry

The first presentation examines the stability or improvement in cognitive processing speed over a two-year period, suggesting the potential of MAVENCLAD to maintain or improve cognitive function in patients with highly active RMS.

Key Points: 
  • The first presentation examines the stability or improvement in cognitive processing speed over a two-year period, suggesting the potential of MAVENCLAD to maintain or improve cognitive function in patients with highly active RMS.
  • Additionally, interim findings from year three of the MAGNIFY-MS extension trial underscore the continued efficacy and safety profile of MAVENCLAD, which is consistent with earlier safety data.
  • These data are being presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024.
  • The post-hoc analysis from 270 patients showed a clinically meaningful benefit in cognitive processing speed in patients treated with MAVENCLAD.

OM1 to Present Research on Multiple Sclerosis at ACTRIMS Forum 2024

Retrieved on: 
星期二, 二月 27, 2024
Technology, Health, Neurology, Artificial Intelligence, Other Science, Other Technology, Research, Managed Care, Networks, General Health, Health Technology, Science, Data Management, Cardiology, Cloud, AI, SPMS, RWD, Conditional sentence, Multiple sclerosis research, Multiple sclerosis, Data, EDSS, RRMS, Disability, Patient, OM1, Poster, Mental health, Medical imaging

The poster will focus on the use of an AI based estimation model used to help characterize disease progression in multiple sclerosis (MS) subtypes using real-world data (RWD).

Key Points: 
  • The poster will focus on the use of an AI based estimation model used to help characterize disease progression in multiple sclerosis (MS) subtypes using real-world data (RWD).
  • WHEN: The presentation will be held on the first day of ACTRIMS Forum 2024 on Thursday, February 29 between 6:00 – 7:30 pm ET.
  • WHY: To effectively monitor disease progression in patients with MS, the measurement of disability is an important component.
  • For insights specific to OM1’s work with multiple sclerosis, including the company’s PremiOM MS dataset, visit the website page here .

Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised

Retrieved on: 
星期一, 一月 8, 2024
Blood pressure, Medical Subject Headings, Marketing, CYP2C9, Agency, INN, Immune system, Lymph, Woman, Movement, Allergy, Heart rate, ATC, Multiple sclerosis, Cryptococcosis, Hypertension, International, Spinal cord, Disease, Headache, Parent, Blood, Language, SPMS, Brain, Cancer, Inflammation, Stroke, Liver, Cardiology, DSM-IV codes, Pregnancy, European Medicines Agency, Lymphocyte, Infection, Tablet, EDSS, EMEA, Select, Cell, Patient, Birth, Checklist, Anatomy, IIA, Medical device

Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis

Retrieved on: 
星期二, 十二月 19, 2023
Neurology, Hospital, Principal, FDA, PET, Disease, Mass, Pharmacist, Microsoft Access, EDSS, Patient, Harvard Medical School, Quality of life, Life, Pharmaceutical industry

NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS).

Key Points: 
  • NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS).
  • Six investigational centers have been recruited for this double-blind, placebo-controlled trial, with up to 18 patients per treatment arm.
  • The primary endpoint of the trial will be the change in microglial activation based on PET scans.
  • I believe the study results will reveal important aspects for optimizing clinical management of na-SPMS - particularly the potential for a reduction in MFIS scores.”

Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Retrieved on: 
星期三, 十一月 8, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, ATRA, EDSS, CDI, Epstein–Barr virus, Biologics license application, PMS, Biomarker, Northwest Biotherapeutics, ASH, Partnership, MS, Disability, Cancer, Autoimmunity, EBV, Patient, BLA

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS).

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS).
  • The study did not meet the primary endpoint of confirmed disability improvement (CDI) by expanded disability status scale (EDSS) at 12 months compared to placebo.
  • In addition, fluid and imaging biomarkers did not provide further supportive evidence.
  • "We are surprised and deeply disappointed with the results of EMBOLD, particularly for the MS patient community which is in urgent need of new treatment options.

WHAT'S NEW: 2024 LEXUS LS

Retrieved on: 
星期三, 十月 25, 2023
Obsidian, Caviar, Lip, EDSS, LSS, Signature, MSRP, Glass, Partnership, Wood, Android Auto, RSA, POI, Drive, CarPlay, Smartphone, AWD, Human, Massage, Maintenance, PDA, Tablet, Traction, LDA, Adaptive cruise control, LS, PCS, Luxury, Torque, Lane departure warning system, Travel, Heat, LTA, Radar, Intelligence, Comfort, Lexus, Multimedia, Metallic, MID, V6, Kiriko, Heavy equipment, Hydraulic machinery, Television, Mobile phone, Road

The 2024 Lexus LS line now comes standard with a wireless cell phone charger located in the cockpit and a brand-new available exterior paint option, Silver Illusion.

Key Points: 
  • The 2024 Lexus LS line now comes standard with a wireless cell phone charger located in the cockpit and a brand-new available exterior paint option, Silver Illusion.
  • 2024 LS gas models come standard with Lexus Safety System+ 3.0 (LSS+ 3.0), Digital Key capability, Head-up Display, and a 12.3-inch MID.
  • The 2024 LS 500 will have a starting MSRP* of $80,685, and the 2024 LS 500h will have an MSRP* of $115,560.
  • 2024 Lexus LS gas models come standard with LSS+ 3.0, an integrated suite of active safety equipment and convenience features.

EQS-News: Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Retrieved on: 
星期二, 十月 17, 2023
Calcium, SPMS, PPMS, MS, EDSS, EBioMedicine, GFAP, Magnetic resonance imaging, Disease, Teaching hospital, Webcast, RRMS, Patient, MRI, AFL, University Hospital of Basel, PMS, PIRA, Disability, Silviculture, Medical imaging, Pharmaceutical industry, Short course immune induction therapy

Serum NfL responses were consistently observed for vidofludimus calcium across progressive MS disease and all subpopulations.

Key Points: 
  • Serum NfL responses were consistently observed for vidofludimus calcium across progressive MS disease and all subpopulations.
  • At 48 weeks (N=79), vidofludimus calcium reduced serum NfL by 10.4% from baseline, compared to a 6.4% increase in placebo.
  • Although early, interim GFAP data also showed a promising signal: at 24 weeks (N=203), GFAP increased by 3.7% for vidofludimus calcium, and 4.4% for placebo.
  • Top-line data from the phase 2 CALLIPER trial of vidofludimus calcium in PMS is expected in April of 2025.